At the outset. it is important to recognize that the dura mater is a connective tissue surrounding the brain and it is not cerebral tissue. The work of Moskowitz (1) has provided ample evidence for neurogenic involvement of the dural vasculature in models of migraine as well as the usefulness of 5HTl-agonists in counteracting the trigemino-vascu1ar responses. Thus, demonstration of 5HTlirreceptor expression in dural vessels is indeed novel and exciting, particularly since previous studies have not clarified if 5lITlIr or 5JIT1O-receptors are present. The few studies of dural arteries have demonstrated high sensitivity to sumatriptan and other 5lITl-agonists (2, 3) . This agonist profile agrees well with the present results. To my knowledge there is no molecular biology study of the expression of 5lIT l-receptor studies in dural arteries. Hamel and colleagues (4, 5) have shown expression of 5JITurreceptor mRNA in human cerebral vessels. These molecular biological observations on cerebral arteries correlate with the present observation of the 5lIT18-receptor protein in human dural arteries. This receptor expression seems well linked with the contractile effectof 5lIT18/1Dagonists.
Another aspect of antimigraine responses is a presynaptic inhibition of sensory nerve activity by the antimigraine drugs (1) . Previous studies of human trigeminal ganglia have shown that both 5HT nr and 5HT1O-receptor mRNA are present (6, 7). Longmore's elegant study (pp. 833-42 in the December 1997 issue of Cephalalgia) has revealed that 5HT1O-receptor protein is present not only in the trigeminal ganglion, but also in its peripheral and central projections. This was taken as evidence in favor of the 5HT1O-receptor being presynaptic, causing inhibition of sensory nerve activation. It is interesting to note that both 5HT10-and 5HT 18immunostaining was seen in the medulla, mainly associated with nerve fibers; for example, the trigeminal sensory system and cells of the trigeminal ganglion. This latter observation agrees well with the previous observations of mRNA expression of 5HT10-and 5HT18receptors in human trigeminal ganglion (6, 7).
It is clear that Longmore's study provides a more detailed appreciation of the 5HTrreceptor distribution in tissue most important for the pathophysiology of migraine and its treatment with 5HT 1B / 1O agonists. droxytryptamine receptor characterization of human cerebral, middle meningeal and temporal arteries: regional differences. 
Flumazenil-responsive stupor
Basilar migraine is typically preceded by visual aura followed by progression of symptoms indicative of cerebellar and brainstem dysfunction. When associated with prominent impairment of consciousness, the symptoms are usually termed confusional migraine (1) . Impairment of consciousness or awareness may last hours to days, and a diverse range of etiologies require exclusion. "Endozepine stupor" (ES) appears to be a clinical entity which can mimic confusional migraine. Work is needed to define this clinical entity that, at present, might better be termed "flumazenil-responsive stupor". Soriani et al, (in the October issue of the journal) report two pediatric cases of FS masquerading as confusional migraine (2) . FS is a disorder of consciousness characterized by ictal elevation of endozepines (particularly endozepine-4) and reversal of symptoms following administration of the benzodiazepine antagonist, flumazenil (3) . An increase in beta power, most marked in the anterior head regions, distinguishes the ictal EEG from other, non-intoxicated states of stupor.
The authors argue strongly for the diagnosis of ES in the second of the presented cases. The diagnosis in the first case is more presumptive and relies on the presence of typical EEG changes and ictal elevation in endozepine-4, but no flumazenil was administered. These two cases add to a growing body of data suggesting that elevated plasma and CSF endozepine concentrations are associated with impairment of consciousness (3, 4) . Proof of endozepine-4 as cause rather than epiphenomenon awaits its structural characterization and the induction of reversible stupor following injection of physiological quantities in animal models.
Elevated endozepine-4 concentrations may be analogous to elevated venous ammonia in hepatic encephalopathy; they may be metabolites of another active compound (thereby explaining the elevated, asymptomatic, postictal endozepine-4 concentration in the second case); or they may actually cause the stuperous state. Regardless of the role of endozepine-4, Soriani and co-authors in their article as well as articles on idiopathic recurring stupor present adequate evidence to support the existence of a flumazenil-responsive stupor, and neurologists should be cognizant of this intriguing clinical entity. blood-brain barrier in significant amounts in therapeutic concentrations.
Other questions are: What is the most effective concentration in the chick retina and how does it correlate with plasma concentration and cerebrospinal levels? The authors state that the concentrations used were high and the dose-effect curve narrow, so it has to be considered whether the effect is specific to 5HT 1B / 1D receptors or an additional effect of the drug when given in relatively high doses. This could of course be analyzed further using more specific concentrations and selective antagonists.
The present studies are interesting and point to a new mechanism for sumatriptan. Further work is necessary, bearing in mind that some studies have not shown positive results in the !:reatment of migraine aura with triptans.
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